[go: up one dir, main page]

MX2024012093A - Agentes de ligacion agonistas del receptor tnf. - Google Patents

Agentes de ligacion agonistas del receptor tnf.

Info

Publication number
MX2024012093A
MX2024012093A MX2024012093A MX2024012093A MX2024012093A MX 2024012093 A MX2024012093 A MX 2024012093A MX 2024012093 A MX2024012093 A MX 2024012093A MX 2024012093 A MX2024012093 A MX 2024012093A MX 2024012093 A MX2024012093 A MX 2024012093A
Authority
MX
Mexico
Prior art keywords
binding agents
receptor binding
tnf receptor
binding
agonistic
Prior art date
Application number
MX2024012093A
Other languages
English (en)
Inventor
Ugur Sahin
Friederike Gieseke
Isil Altintas
David Satijn
Paul Parren
Original Assignee
Biontech Ag
Genmab As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biontech Ag, Genmab As filed Critical Biontech Ag
Publication of MX2024012093A publication Critical patent/MX2024012093A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75—Agonist effect on antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biomedical Technology (AREA)
  • Oncology (AREA)
  • General Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Pain & Pain Management (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Communicable Diseases (AREA)
  • Rheumatology (AREA)
  • Transplantation (AREA)
  • Biotechnology (AREA)
  • Diabetes (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Peptides Or Proteins (AREA)

Abstract

La presente invención se refiere a agentes de ligación que se enlazan a receptores de la superfamilia TNF, en particular a agentes de ligación que se ligan a al menos dos receptores diferentes de la superfamilia TNF, así como a su uso en la medicina. La presente invención se refiere además a moléculas de ácido nucleico que codifican estos agentes de ligación, a células que comprenden estas moléculas de ácido nucleico y/o composiciones farmacéuticas, de igual manera en la presente solicitud se describen kits que comprenden agentes de ligación que se enlazan a receptores de la superfamilia TNF.
MX2024012093A 2015-01-08 2017-07-05 Agentes de ligacion agonistas del receptor tnf. MX2024012093A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP2015050255 2015-01-08
PCT/EP2016/050308 WO2016110584A1 (en) 2015-01-08 2016-01-08 Agonistic tnf receptor binding agents

Publications (1)

Publication Number Publication Date
MX2024012093A true MX2024012093A (es) 2024-11-08

Family

ID=55072677

Family Applications (3)

Application Number Title Priority Date Filing Date
MX2017008917A MX377773B (es) 2015-01-08 2016-01-08 Agentes de ligacion agonistas del receptor tnf.
MX2020012240A MX2020012240A (es) 2015-01-08 2017-07-05 Agentes de ligacion agonistas del receptor tnf.
MX2024012093A MX2024012093A (es) 2015-01-08 2017-07-05 Agentes de ligacion agonistas del receptor tnf.

Family Applications Before (2)

Application Number Title Priority Date Filing Date
MX2017008917A MX377773B (es) 2015-01-08 2016-01-08 Agentes de ligacion agonistas del receptor tnf.
MX2020012240A MX2020012240A (es) 2015-01-08 2017-07-05 Agentes de ligacion agonistas del receptor tnf.

Country Status (25)

Country Link
US (4) US10457735B2 (es)
EP (3) EP3242890B1 (es)
JP (4) JP6744326B2 (es)
KR (3) KR102238326B1 (es)
CN (3) CN117843799A (es)
AU (2) AU2016205974B2 (es)
BR (1) BR112017013189B1 (es)
CA (2) CA2969888A1 (es)
CY (2) CY1122399T1 (es)
DK (2) DK3623386T3 (es)
ES (2) ES2922398T3 (es)
HR (2) HRP20220811T1 (es)
HU (2) HUE048532T2 (es)
LT (1) LT3623386T (es)
ME (1) ME03576B (es)
MX (3) MX377773B (es)
PL (2) PL3242890T3 (es)
PT (2) PT3242890T (es)
RS (2) RS63384B1 (es)
RU (1) RU2723131C2 (es)
SG (2) SG11201704597WA (es)
SI (2) SI3242890T1 (es)
SM (2) SMT202200288T1 (es)
WO (1) WO2016110584A1 (es)
ZA (1) ZA201704797B (es)

Families Citing this family (78)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12466897B2 (en) 2011-10-10 2025-11-11 Xencor, Inc. Heterodimeric human IgG1 polypeptides with isoelectric point modifications
US9605084B2 (en) 2013-03-15 2017-03-28 Xencor, Inc. Heterodimeric proteins
US11053316B2 (en) 2013-01-14 2021-07-06 Xencor, Inc. Optimized antibody variable regions
US10738132B2 (en) 2013-01-14 2020-08-11 Xencor, Inc. Heterodimeric proteins
US10968276B2 (en) 2013-03-12 2021-04-06 Xencor, Inc. Optimized anti-CD3 variable regions
US10858417B2 (en) 2013-03-15 2020-12-08 Xencor, Inc. Heterodimeric proteins
LT3122781T (lt) 2014-03-28 2020-03-25 Xencor, Inc. Bispecifiniai antikūnai, kurie jungiasi prie cd38 ir cd3
IL252467B (en) 2014-11-26 2022-06-01 Xencor Inc Heterodimeric antibodies that bind cd3 and cd38
US10259887B2 (en) 2014-11-26 2019-04-16 Xencor, Inc. Heterodimeric antibodies that bind CD3 and tumor antigens
TN2017000223A1 (en) 2014-11-26 2018-10-19 Xencor Inc Heterodimeric antibodies that bind cd3 and tumor antigens
CN115109158A (zh) 2015-05-07 2022-09-27 阿吉纳斯公司 抗ox40抗体及其使用方法
TW202134282A (zh) 2015-12-02 2021-09-16 美商艾吉納斯公司 抗體和使用彼之方法
KR20180085800A (ko) 2015-12-07 2018-07-27 젠코어 인코포레이티드 Cd3 및 psma에 결합하는 이종이합체성 항체
BR112018012374A2 (pt) 2015-12-16 2018-12-04 Gritstone Oncology, Inc. identificação, fabricação e uso de neoantígeno
RU2018139339A (ru) 2016-04-22 2020-05-22 Эллигейтор Биосайенс Аб Новые биспецифические полипептиды против cd137
MA45255A (fr) 2016-06-14 2019-04-17 Xencor Inc Anticorps inhibiteurs de points de contrôle bispécifiques
CA3029328A1 (en) 2016-06-28 2018-01-04 Xencor, Inc. Heterodimeric antibodies that bind somatostatin receptor 2
EP3484922A1 (en) * 2016-07-14 2019-05-22 Genmab A/S Multispecific antibodies against cd40 and cd137
AU2017321625A1 (en) * 2016-08-30 2019-04-04 Xencor, Inc. Bispecific immunomodulatory antibodies that bind costimulatory and checkpoint receptors
WO2018045110A1 (en) * 2016-08-30 2018-03-08 Xencor, Inc. Bispecific immunomodulatory antibodies that bind costimulatory and checkpoint receptors
US10793632B2 (en) 2016-08-30 2020-10-06 Xencor, Inc. Bispecific immunomodulatory antibodies that bind costimulatory and checkpoint receptors
EA201990578A1 (ru) * 2016-09-23 2019-10-31 Связывающие молекулы, которые модулируют биологическую активность, проявляемую клеткой
CA3041340A1 (en) 2016-11-09 2018-05-17 Agenus Inc. Anti-ox40 antibodies, anti-gitr antibodies, and methods of use thereof
KR20240161216A (ko) 2017-01-20 2024-11-12 하이델베르크 파마 리서치 게엠베하 Cd137+ 세포의 고갈을 위한 조성물 및 방법
EP3601348A1 (en) * 2017-03-29 2020-02-05 Glycotope GmbH Humanized anti-cd40 antibodies
IL272103B2 (en) 2017-07-20 2024-10-01 Aptevo Res & Development Llc Antigen binding proteins binding to 5T4 and 4-1BB and related compositions and methods of treating cancer
CA3071211A1 (en) * 2017-08-04 2019-02-07 Genmab A/S Binding agents binding to pd-l1 and cd137 and use thereof
WO2019035938A1 (en) 2017-08-16 2019-02-21 Elstar Therapeutics, Inc. MULTISPECIFIC MOLECULES BINDING TO BCMA AND USES THEREOF
US11535667B2 (en) * 2017-08-28 2022-12-27 Systimmune, Inc. Anti-CD3 antibodies and methods of making and using thereof
JP7227237B2 (ja) 2017-10-10 2023-02-21 グリットストーン バイオ インコーポレイテッド ホットスポットを利用した新生抗原の特定
US11312770B2 (en) 2017-11-08 2022-04-26 Xencor, Inc. Bispecific and monospecific antibodies using novel anti-PD-1 sequences
US10981992B2 (en) 2017-11-08 2021-04-20 Xencor, Inc. Bispecific immunomodulatory antibodies that bind costimulatory and checkpoint receptors
KR102905054B1 (ko) 2017-11-22 2025-12-29 시애틀 프로젝트 코포레이션 신생항원에 대한 접합 에피토프 제시 감소
JP7765181B2 (ja) 2017-12-19 2025-11-06 ゼンコア インコーポレイテッド 改変されたｉｌ－２ ｆｃ融合タンパク質
EP3737692A4 (en) 2018-01-09 2021-09-29 Elstar Therapeutics, Inc. CALRETICULIN AND MODIFIED T-LYMPHOCYTES BINDING CONSTRUCTIONS FOR THE TREATMENT OF DISEASES
WO2019178362A1 (en) 2018-03-14 2019-09-19 Elstar Therapeutics, Inc. Multifunctional molecules that bind to calreticulin and uses thereof
US10982006B2 (en) 2018-04-04 2021-04-20 Xencor, Inc. Heterodimeric antibodies that bind fibroblast activation protein
CA3097741A1 (en) 2018-04-18 2019-10-24 Xencor, Inc. Tim-3 targeted heterodimeric fusion proteins containing il-15/il-15ra fc-fusion proteins and tim-3 antigen binding domains
CN112867734A (zh) 2018-04-18 2021-05-28 Xencor股份有限公司 包含IL-15/IL-15Ra Fc融合蛋白和PD-1抗原结合结构域的靶向PD-1的异源二聚体融合蛋白及其用途
CN112955465A (zh) 2018-07-03 2021-06-11 马伦戈治疗公司 抗tcr抗体分子及其用途
GB201811415D0 (en) 2018-07-12 2018-08-29 F Star Beta Ltd Anti-Mesothelin Anti bodies
GB201811450D0 (en) 2018-07-12 2018-08-29 F Star Delta Ltd Mesothelin and CD137 binding molecules
GB201811404D0 (en) * 2018-07-12 2018-08-29 F Star Beta Ltd Anti-CD137 Antibodies
WO2020011964A1 (en) 2018-07-12 2020-01-16 F-Star Beta Limited Antibody molecules that bind pd-l1 and cd137
JP7598312B2 (ja) 2018-07-23 2024-12-11 ハイデルベルク ファーマ リサーチ ゲーエムベーハー 同種異系の細胞療法における抗－ｃｄ１３７抗体薬物コンジュゲート（ａｄｃ）の使用
AU2019355971B2 (en) 2018-10-03 2025-05-08 Xencor, Inc. IL-12 heterodimeric Fc-fusion proteins
WO2020072996A1 (en) 2018-10-05 2020-04-09 Seattle Children's Hospital (D/B/A Seattle Children's Research Institute) Newborn screening for primary immunodeficiencies, cystinosis, and wilson disease
CN113454111A (zh) 2018-11-06 2021-09-28 健玛保 抗体配制剂
JP7463366B2 (ja) * 2018-11-20 2024-04-08 タケダ ワクチン，インコーポレイテッド 新規の抗ジカウイルス抗体及びその使用
WO2020172605A1 (en) 2019-02-21 2020-08-27 Elstar Therapeutics, Inc. Antibody molecules that bind to nkp30 and uses thereof
CN114026122B (zh) 2019-02-21 2024-12-31 马伦戈治疗公司 结合t细胞相关癌细胞的多功能分子及其用途
BR112021016955A2 (pt) 2019-03-01 2021-11-23 Xencor Inc Composição, composição de ácido nucleico, composição de vetor de expressão, vetor de expressão, célula hospedeira, métodos de produção de um domínio de ligação de membro de família 3 de pirofosfatase/fosfodiesterase de ectonucleotídeo e de tratamento de um câncer, anticorpo anti-enpp3, e, anticorpo heterodimérico
BR112021021165A2 (pt) 2019-04-24 2022-01-04 Heidelberg Pharma Res Gmbh Conjugados anticorpo-fármaco de amatoxina e uso dos mesmos
EP4084823A4 (en) 2020-01-03 2024-05-15 Marengo Therapeutics, Inc. ANTI-TCR ANTIBODY MOLECULES AND THEIR USES
IL294967A (en) 2020-02-04 2022-09-01 Genmab As Antibodies for use in therapy
WO2021202807A1 (en) * 2020-03-31 2021-10-07 Seattle Children's Hospital D/B/A Seattle Children's Research Institute Proteomic screening for lysosomal storage diseases
EP4126939A4 (en) 2020-04-02 2024-08-21 Seattle Children's Hospital d/b/a Seattle Children's Research Institute ANTIBODIES THAT BIND SPECIFICALLY TO PEPTIDES ASSOCIATED WITH PRIMARY IMMUNODEFICIENCIES: WISKOTT-ALDRICH SYNDROME AND X-LINKED AGAMMAGLOBULINEMIA
US11919956B2 (en) 2020-05-14 2024-03-05 Xencor, Inc. Heterodimeric antibodies that bind prostate specific membrane antigen (PSMA) and CD3
WO2022036495A1 (en) 2020-08-17 2022-02-24 Utc Therapeutics Inc. Lymphocytes-antigen presenting cells co-stimulators and uses thereof
KR20230166150A (ko) 2020-08-19 2023-12-06 젠코어 인코포레이티드 항-cd28 조성물
EP4228674A4 (en) * 2020-10-15 2025-01-29 Bioincept LLC SYSTEMS, COMPOSITIONS AND METHODS FOR DETERMINING THE VIABILITY OF EMBRYOS
CN112175080B (zh) * 2020-10-22 2021-05-25 优睿赛思(武汉)生物科技有限公司 抗人白介素-6高亲和力兔单克隆抗体及应用
EP4255575A2 (en) 2020-12-07 2023-10-11 Genmab A/S Antibody and taxane combination therapy
US11739144B2 (en) 2021-03-09 2023-08-29 Xencor, Inc. Heterodimeric antibodies that bind CD3 and CLDN6
IL305681A (en) * 2021-03-09 2023-11-01 Genmab As Multispecific binding agents against cd40 and cd137 in therapy
KR20230154311A (ko) 2021-03-10 2023-11-07 젠코어 인코포레이티드 Cd3 및 gpc3에 결합하는 이종이량체 항체
WO2022216993A2 (en) 2021-04-08 2022-10-13 Marengo Therapeutics, Inc. Multifuntional molecules binding to tcr and uses thereof
CN115433277A (zh) * 2021-06-05 2022-12-06 苏州缔码生物科技有限公司 抗cd38兔重组单克隆抗体的制备及应用
WO2022268740A1 (en) 2021-06-21 2022-12-29 Genmab A/S Combination dosage regime of cd137 and pd-l1 binding agents
US20240059782A1 (en) * 2022-03-01 2024-02-22 Agilent Technologies, Inc. Anti-human b cell maturation antigen (bcma) antibodies and their use in immunohistochemistry (ihc)
EP4577577A1 (en) * 2022-08-27 2025-07-02 H. Lee Moffitt Cancer Center & Research Institute, Inc. Cd40l 41bbl bispecific proteins
CN121285385A (zh) 2023-05-12 2026-01-06 金麦安博股份有限公司 能够与ox40结合的抗体、其变体及其用途
CN117069848B (zh) * 2023-08-02 2025-02-28 武汉爱博泰克生物科技有限公司 抗人cd146兔单克隆抗体及其应用
TW202540189A (zh) 2023-11-30 2025-10-16 德商生物新技術公司 在組合療法中能夠結合ｏｘ４０之抗體
CN118440198B (zh) * 2024-04-03 2024-11-15 武汉爱博泰克生物科技有限公司 抗人cd69蛋白的兔单克隆抗体及其应用
CN118620078B (zh) * 2024-07-09 2024-11-19 武汉爱博泰克生物科技有限公司 抗人cd45ra蛋白的抗体、抗体偶联物及其应用
CN118453854B (zh) * 2024-07-12 2024-10-29 广州粤华制药有限公司 一种用于建立慢性肾小球肾病模型的组合物及其应用
CN119431591B (zh) * 2024-12-16 2025-08-05 无锡傲锐东源生物科技有限公司 抗人psp蛋白的单克隆抗体及其应用

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7754208B2 (en) 2001-01-17 2010-07-13 Trubion Pharmaceuticals, Inc. Binding domain-immunoglobulin fusion proteins
US20030133939A1 (en) 2001-01-17 2003-07-17 Genecraft, Inc. Binding domain-immunoglobulin fusion proteins
US20050123536A1 (en) * 2001-11-20 2005-06-09 Che-Leung Law Treatment of immunological disorders using anti-dc30 antibodies
CN101023102B (zh) * 2004-09-17 2013-05-29 霍夫曼-拉罗奇有限公司 抗-ox40l抗体
EP3613767A1 (en) 2005-05-18 2020-02-26 Ablynx N.V. Improved nanobodiestm against tumor cecrosis factor-alpha
NZ591252A (en) * 2006-03-17 2012-06-29 Biogen Idec Inc Methods of designing antibody or antigen binding fragments thereof with substituted non-covarying amino acids
GB0620894D0 (en) * 2006-10-20 2006-11-29 Univ Southampton Human immune therapies using a CD27 agonist alone or in combination with other immune modulators
JP2010518873A (ja) 2007-02-27 2010-06-03 ジェネンテック， インコーポレイテッド アンタゴニスト抗ｏｘ４０抗体および炎症性疾患および自己免疫性疾患の処置におけるその使用
MX2009010282A (es) 2007-03-29 2009-10-12 Genmab As Anticuerpos biespecificos y metodos para su produccion.
WO2009034172A1 (en) * 2007-09-14 2009-03-19 Vrije Universiteit Brussel Enhancing the t-cells stimulatory capacity of human antigen presenting cells and their use in vaccination
PT2594590E (pt) 2007-12-14 2015-01-14 Bristol Myers Squibb Co Moléculas de ligação ao recetor humano ox40
US9931386B2 (en) 2008-06-16 2018-04-03 Atsuo Ochi Recombinant multiple domain fusion protein mitogens and use thereof for inducing enhancement or repression of antigen-specific immunity
MX2011008697A (es) 2009-02-17 2011-11-18 Ucb Pharma Sa Moleculas de anticuerpos que tiene especificidad para ox40 humano.
AU2011275749C1 (en) 2010-07-09 2015-09-17 Aduro Biotech Holdings, Europe B.V. Agonistic antibody to CD27
PL2663580T3 (pl) 2011-01-10 2017-08-31 Ct Atlantic Ltd. Terapia skojarzona obejmująca przeciwciała wiążące antygen związany z nowotworem
EA036047B1 (ru) 2011-07-11 2020-09-18 Икнос Сайенсиз Са Антитела, которые связываются с ox40, и их применение
CA2845810C (en) * 2011-08-23 2017-03-28 Board Of Regents, The University Of Texas System Anti-ox40 antibodies and methods of using the same
GB201116092D0 (en) 2011-09-16 2011-11-02 Bioceros B V Antibodies and uses thereof
EP2976361B1 (en) * 2013-03-18 2018-07-18 BiocerOX Products B.V. Humanized anti-cd134 (ox40) antibodies and uses thereof
TW201619200A (zh) * 2014-10-10 2016-06-01 麥迪紐有限責任公司 人類化抗－ｏｘ４０抗體及其用途
EP3484922A1 (en) * 2016-07-14 2019-05-22 Genmab A/S Multispecific antibodies against cd40 and cd137

Also Published As

Publication number Publication date
JP2018506298A (ja) 2018-03-08
JP6950056B2 (ja) 2021-10-13
ES2922398T3 (es) 2022-09-14
EP4071176A3 (en) 2022-12-14
HUE048532T2 (hu) 2020-07-28
RU2017127792A3 (es) 2019-06-17
CY1122399T1 (el) 2020-11-25
RS59693B1 (sr) 2020-01-31
RU2723131C2 (ru) 2020-06-08
HRP20220811T1 (hr) 2022-09-30
KR102640769B1 (ko) 2024-02-27
ZA201704797B (en) 2019-05-29
DK3623386T3 (da) 2022-07-04
CN109476761A (zh) 2019-03-15
US20210253725A1 (en) 2021-08-19
KR20170132717A (ko) 2017-12-04
JP2020188797A (ja) 2020-11-26
CA3224830A1 (en) 2016-07-14
JP7390345B2 (ja) 2023-12-01
EP3242890A1 (en) 2017-11-15
US20200079866A1 (en) 2020-03-12
JP2023085435A (ja) 2023-06-20
BR112017013189B1 (pt) 2024-03-05
JP7487376B2 (ja) 2024-05-20
KR102238326B1 (ko) 2021-04-12
MX2017008917A (es) 2018-02-09
CN111499752A (zh) 2020-08-07
KR20240028548A (ko) 2024-03-05
SG10202003171TA (en) 2020-05-28
US10927181B2 (en) 2021-02-23
ES2755527T3 (es) 2020-04-22
MX2020012240A (es) 2021-02-22
CA2969888A1 (en) 2016-07-14
SG11201704597WA (en) 2017-07-28
KR20210041634A (ko) 2021-04-15
EP3623386A1 (en) 2020-03-18
EP4071176A2 (en) 2022-10-12
US12421319B2 (en) 2025-09-23
JP6744326B2 (ja) 2020-08-19
ME03576B (me) 2020-07-20
CN109476761B (zh) 2020-01-10
AU2016205974A1 (en) 2017-07-13
PL3623386T3 (pl) 2022-08-08
BR112017013189A2 (pt) 2018-04-10
CN117843799A (zh) 2024-04-09
JP2022025064A (ja) 2022-02-09
KR102838719B1 (ko) 2025-07-28
RU2017127792A (ru) 2019-02-08
US10457735B2 (en) 2019-10-29
MX377773B (es) 2025-03-11
CY1125349T1 (el) 2025-05-09
SI3242890T1 (sl) 2020-01-31
AU2016205974B2 (en) 2021-11-04
AU2022200571B2 (en) 2024-11-21
RU2020115901A (ru) 2020-08-05
WO2016110584A1 (en) 2016-07-14
HRP20191824T1 (hr) 2020-01-24
US20240254249A1 (en) 2024-08-01
CN111499752B (zh) 2024-05-31
US20180194849A1 (en) 2018-07-12
SI3623386T1 (sl) 2022-09-30
EP3623386B1 (en) 2022-04-13
US11814411B2 (en) 2023-11-14
SMT201900702T1 (it) 2020-01-14
SMT202200288T1 (it) 2022-09-14
RS63384B1 (sr) 2022-08-31
PL3242890T3 (pl) 2020-04-30
PT3623386T (pt) 2022-07-18
LT3623386T (lt) 2022-08-10
AU2022200571A1 (en) 2022-02-17
HUE059219T2 (hu) 2022-10-28
EP3242890B1 (en) 2019-09-04
DK3242890T3 (da) 2019-10-21
PT3242890T (pt) 2019-12-10
NZ733157A (en) 2021-10-29

Similar Documents

Publication Publication Date Title
MX2020012240A (es) Agentes de ligacion agonistas del receptor tnf.
PH12018500714A1 (en) Anti-tigit antigen-binding proteins and methods of use thereof
PH12020500500A1 (en) Pyrazolopyrimidinone compounds and uses thereof
MX2021010668A (es) Proteinas de fusion de citoquinas.
EA201792047A1 (ru) Новые соединения
MX381456B (es) Regulador de ph de transduccion.
NZ737399A (en) Ccr2 modulators
EA201491973A1 (ru) Новые соединения
PH12014501351A1 (en) Fluorinated estrogen receptor modulators and uses thereof
PH12014502095A1 (en) Estrogen receptor modulators and uses thereof
EA201691853A1 (ru) Агонисты мускариновых рецепторов
MX2015016171A (es) Moduladores del receptor de estrogeno de azetidina y usos de los mismos.
WO2015109124A3 (en) Immunomodulatory agents
CL2014001254A1 (es) Molécula de unión biespecífica para bcma y cd3; secuencia de ácido nucleico que la codifica; vector ; célula; composición farmacéutica que comprende a la molécula de unión; uso para tratar enfermedades relacionadas a transtornos de células plasmáticas, trastornos de células b correlacionados con la expresión de bcma y enfermedades autoinmunes.
MX2015011779A (es) Nucleosidos biciclicos unidos en puente.
EA201691674A1 (ru) 1,2-замещенные циклопентаны в качестве антагонистов рецептора орексина
MX2018000352A (es) 4-azaindoles sustituidos y su uso como moduladores del receptor glun2b.
EA201790461A1 (ru) Композиции внеклеточного матрикса
MY188405A (en) Anti-cd154 antibodies and methods of using them
WO2014159669A3 (en) Aptamers that bind to il-6 and their use in treating or diagnosing il-6 mediated conditions
SA516370737B1 (ar) Cgrp صيغ لمضادات مستقبل
MX2022006304A (es) Composiciones y metodos para inhibir la actividad biologica de biomoleculas solubles.
EA201501123A8 (ru) Новые (циано-диметил-метил)-изоксазолы и -[1,3,4]тиадиазолы
MX2017003216A (es) Uso de antagonistas de il-17 para inhibir la progresion del daño estructural en pacientes con artritis psoriasica.
MX364912B (es) Antagonistas / agonistas inversos del receptor canabinoide.